Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Thermo Fisher Scientific    TMO

THERMO FISHER SCIENTIFIC

(TMO)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Thermo Fisher Scientific : iSPA Workflow Helps Pharmaceutical Companies Bring New Drugs to Market Faster

share with twitter share with LinkedIn share with facebook
06/17/2020 | 07:42am EDT

To help pharmaceutical companies obtain faster results in their drug discovery process and reduce the cost of bringing new drugs to market, Thermo Fisher Scientific has released the Thermo Scientific iSPA Workflow, the first commercially available single particle analysis (SPA) workflow solution.

As pharmaceutical labs turn to cryo-electron microscopy (cryo-EM) to uncover the structures of difficult-to-crystalize molecules at near atomic resolution, they need ways to increase their productivity to more quickly move from early drug discovery to clinical trials.

iSPA Workflow solves this problem by providing an easy-to-use, highly productive and automation-enhanced solution to match the pace of drug discovery. Developed with input from users in the pharmaceutical industry, this SPA dedicated workflow is designed for structural biologists of all experience levels who need to deliver structural insights. With reduced manual steps, the workflow is simplified and preparing the microscope for data collection takes less than 30 minutes.

Companies can also increase productivity by using its unattended data collection feature, which allows them to collect data from multiple grids while not at the instrument. The solution offers uptime reliability of instruments, helping users avoid time spent troubleshooting equipment problems.

'Our iSPA Workflow changes the game for pharmaceutical companies by dramatically increasing their throughput with a high-quality, easy-to-use instrument that quadruples productivity compared to our current cryo-EM workflow,' said Trisha Rice, vice president and general manager of life sciences at Thermo Fisher. 'The result is a convenient and reliable solution that reduces barriers to cryo-EM adoption and accelerates the path to new, more effective drugs.'

Dr. Giovanna Scapin, Chief Scientist at NanoImaging Services, remarked on the throughput improvement and improved automation of the iSPA workflow, 'Receiving the data we need overnight, versus a week, allows us to solve several structures as opposed to one. Automated data collection means that we can schedule a full weekend run on six grids without having to manually change them, improving the time requested from sample to structure.'

The flagship of the iSPA workflow is the Thermo Scientific Krios Rx, a high-end cryo-transmission electron microscope (cryo-TEM) designed specifically for ease-of-use and enhanced automation. Automation facilitates unattended data collection, and requires minimal expertise to operate the microscope, freeing up time to focus on results.

The Krios Rx is equipped with a Falcon 4 Direct Electron Detector and EPU Quality Monitoring software, which allows users to optimize the quality of data as it's being collected. The new Electron Event Representation data format of the Falcon 4 enables substantial lossless data compression, while retaining super-resolution information. Finally, a robust and fully integrated solution with productivity and throughput of more than 400 high-quality movies per hour, helps users quickly generate new and repeat structures.

The Krios Rx comes bundled with Accelerate Rx, a unique service package that guarantees a 90 percent uptime usage of the instrument during the warranty period. Accelerate Rx is an outcome-based service package that also includes application training, remote applications support, workflow validation, a workflow application and a customer dashboard with productivity and uptime reporting.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue exceeding $25 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, improving patient diagnostics and therapies or increasing productivity in their laboratories, we are here to support them. Our global team of more than 75,000 colleagues delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services and Patheon.

Contact:

Tel: +1 971-330-8955

Email: laura.glass@thermofisher.com

(C) 2020 Electronic News Publishing, source ENP Newswire

share with twitter share with LinkedIn share with facebook
Latest news on THERMO FISHER SCIENTIFIC
08/07THERMO FISHER SCIENTIFIC : Accelerates Nanometer-Scale Research with Next-Genera..
AQ
08/07THERMO FISHER SCIENTIFIC : Versatile Thermo Scientific Helios 5 PFIBs Enable Mat..
AQ
08/06Davidson Kempner says again it will not be tendering Qiagen shares
RE
08/06Davidson Kempner says again it will not be tendering Qiagen shares
RE
08/05THERMO FISHER SCIENTIFIC : 's COVID-19 Response Continues to Expand with New Hig..
PR
08/05The Global pH Sensors & Analyzers Market to Garner $1939.5 Million by 2028
AQ
08/04THERMO FISHER SCIENTIFIC INC. : Other Events, Financial Statements and Exhibits ..
AQ
08/04THERMO FISHER SCIENTIFIC : Confirms Offer to Acquire QIAGEN Shares Expires on Au..
PR
08/04THERMO FISHER SCIENTIFIC : OIE Approves Registration of VetMAX African Swine Fev..
AQ
08/03THERMO FISHER SCIENTIFIC : China Approves Thermo Fisher Scientific's African Swi..
PU
More news
Financials (USD)
Sales 2020 28 041 M - -
Net income 2020 4 456 M - -
Net Debt 2020 12 658 M - -
P/E ratio 2020 37,0x
Yield 2020 0,21%
Capitalization 164 B 164 B -
EV / Sales 2020 6,30x
EV / Sales 2021 5,92x
Nbr of Employees 75 000
Free-Float 90,6%
Chart THERMO FISHER SCIENTIFIC
Duration : Period :
Thermo Fisher Scientific Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends THERMO FISHER SCIENTIFIC
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 19
Average target price 442,72 $
Last Close Price 414,33 $
Spread / Highest target 20,7%
Spread / Average Target 6,85%
Spread / Lowest Target -34,6%
EPS Revisions
Managers
NameTitle
Marc N. Casper Chairman, President & Chief Executive Officer
Mark P. Stevenson Chief Operating Officer & Executive Vice President
Stephen Williamson Chief Financial Officer & Senior Vice President
Ryan Snyder Chief Information Officer & Senior Vice President
Scott M. Sperling Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
THERMO FISHER SCIENTIFIC27.54%163 905
DANAHER CORPORATION33.83%145 918
INTUITIVE SURGICAL, INC.16.02%80 894
ILLUMINA, INC.7.21%58 702
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.79.97%58 573
BOSTON SCIENTIFIC CORPORATION-13.82%54 208